Dual Vaccine Trial in Myeloproliferative Neoplasms - MPN Voice

MPN Voice

10,834 members15,131 posts

Dual Vaccine Trial in Myeloproliferative Neoplasms

Manouche profile image
7 Replies

Brief Summary:

A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and Aginase1 peptides with Montanide ISA-51 as adjuvant, to monitor the immunological response to vaccination and subsequently safety, toxicity and clinical effect.

Primary Purpose:Treatment

Official Title:Dual Vaccine Trial in Myeloproliferative Neoplasms

Estimated Study Completion Date :July 10, 2022

Primary Outcome Measures :

Immune response [ Time Frame: 1 year ]

T-cell cytokine release towards target antigens

Secondary Outcome Measures :

Adverse events evaluated by CTCAE v. 5.0 [ Time Frame: 1 year ]

Adverse events are graded 1-5 according to the criteria

Clinical response [ Time Frame: 10 year ]

Vaccinations will induce clinical response in 2 patients, either partial response or better, according response criteria for PV and ET or clinical response as a reduction of mutated allelic burden - 10% from baseline at any time.

clinicaltrials.gov/ct2/show...

Written by
Manouche profile image
Manouche
To view profiles and participate in discussions please or .
Read more about...
7 Replies
Bluetop profile image
Bluetop

Oh, a vaccine would be good!

light profile image
light

Hi there, thank you for posting this info. Great news for us all. Wishing you well

Aneliv9 profile image
Aneliv9

This could be therapeutical?

Manouche profile image
Manouche in reply toAneliv9

The vaccine could be therapeutical. « the combination of vaccines with interferon-alpha (IFN-α) is a most interesting option. IFN-α is a potent immunostimulatory cytokine and has been used for years for the treatment of MPN. IFN-α has been shown to induce complete hematological responses and major molecular remissions in a substantial proportion of patients. Concurrently, treatment with IFN-α induces marked alterations in immune cell subsets and in the expression of HLA-related genes, and the mechanism beyond the clinical effet of IFN-α is believed to rely partially on the induction of an anti-tumor immune response. Previous reports on therapeutic cancer vaccination in other malignancies have underscored the importance of a low tumor burden at the time of vaccine initiation in order to obtain a proper clinical response. As IFN-α is the only drug, which is able to reduce the tumor burden in a substantial part of the patients, it is most apparent to reduce the tumor burden with IFN-α, and after attainment of a major molecular remission, initiate therapeutic cancer vaccination against the targets described above. This could hopefully eradicate the malignant clone and ultimately cure the patient.

frontiersin.org/articles/10...

Aneliv9 profile image
Aneliv9 in reply toManouche

I am.sorry to asking you again, i will read the whole study after this quick question! This vaccine is the same as the drug that is being injected?

Aneliv9 profile image
Aneliv9 in reply toManouche

This article is from 2018... Is there any progress?? Do you believe scientists still working on this vaccine? Or maybe is.an abandoned theory?

Manouche profile image
Manouche in reply toAneliv9

Hi Aneliv,

As mentioned on the first article, the vaccine is being tested on a clinical trial finishing in July 2022.

Not what you're looking for?

You may also like...

Dual Vaccine Trial in Myeloproliferative Neoplasms

Brief Summary: « A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and...
Manouche profile image

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

«  Patients with PV often have high JAK2 V 617F VAF (>50%) because of the emergence of a dominant...
Manouche profile image

Really??: Pruritus May Mark Severe Symptomology in Myeloproliferative Neoplasms"- From "Hematology Advisor"- Some surprising findings...

In myeloproliferative neoplasms (MPNs), patients reporting pruritus had more symptoms, greater...
PhysAssist profile image

FDA Approves Ropeginterferon Alfa-2b-njft for Polycythemia Vera

The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for use as a treatment in patients...
JT_Marlin profile image